Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Amy Simon sold 6,700 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total transaction of $164,686.00. Following the transaction, the insider directly owned 102,735 shares of the company's stock, valued

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 5,956 shares of Beam Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $146,398.48. Following the sale, the insider owned 109,711 shares in the company, valued at $2,696,696.38.

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) President Giuseppe Ciaramella sold 11,810 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total transaction of $290,289.80. Following the completion of the transaction, the president owned 218,406 shares in

SG Americas Securities LLC lifted its stake in shares of Beam Therapeutics Inc. (NASDAQ: BEAM) by 139.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 103,469 shares of the company's stock after buying an additional 60,249 shares during the

Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)

Beam Therapeutics (NASDAQ: BEAM) executives and clinical collaborators presented updated top-line data from the company's ongoing Phase I/II study of BEAM-302, an in vivo base-editing therapy being evaluated in patients with alpha-1 antitrypsin deficiency (AATD). The call focused on efficacy and safety results from 29 treated patients as of a February 10, 2026 data cutoff, along

Beam Therapeutics reports promising phase I/II data for BEAM-302 in AATD, showing strong efficacy, tolerability and potential as a one-time curative treatment.

Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

BEAM-302 is Beam's lead genetic disease program for liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease.

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up